Axsome Therapeutics Stock News

These three developmental-stage pharma stocks are attracting some of the smartest investors right now.

The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences

Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.

Fly Intel: Pre-market Movers CODX AXSM SEAS TEN XBIT TSLA SMPL DGLY DAL TDY MNLO

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (AXSM) today and set a price target of $200.00. The company's shares

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics ( AXSM – Research Report ) today and set a price target of $200.00 . The company’s shares closed last Friday at

Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond.

Adaptive Biotechnologies and Axsome Therapeutics are under-followed stocks with large upsides.

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (SGEN), Minerva Neurosciences (NERV) and

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics ( SGEN – Research Report ), Minerva Neurosciences ( NERV – Research Report ) and O

The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3

These drug developers just released new clinical trial results.

Q4 2019 Axsome Therapeutics Inc Earnings Call

Success in clinical trials doesn't guarantee success on the market.

Axsome's (AXSM) AXS-05 meets key secondary endpoints in late-stage study for addressing patients with treatment resistant depression. However, the primary endpoint did not reach statistical significan